To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Markets
2 views
Opus Genetics: A Resounding Study Success Merits A Higher Valuation
Opus Genetics (IRD) receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. Click to read.
Seekingalpha Verified Source
Reported by Edmund Ingham · Syndicated via official news feed
Explore all Markets stories
Syndicated feed content with full publisher credit.
Markets Desk
More in Markets
Continue reading verified coverage and related developments on this desk.
